Details for Patent: 12,447,241

Which drugs does patent 12,447,241 protect, and when does it expire?

Patent 12,447,241 protects INLEXZO and is included in one NDA.

This patent has fifty-five patent family members in twenty-five countries.

Summary for Patent: 12,447,241

Title:	Multi-unit drug delivery devices and methods
Abstract:	Implantable drug delivery devices include a housing defining a reservoir, a first unit within the reservoir, and a second unit within the reservoir. The first unit contains a drug and the second unit contains a functional agent that facilitates release of the drug. Intravesical drug delivery devices include a housing portion containing a drug formulation and a housing portion containing an excipient, and are configured to release the drug according to a first release profile and the excipient according to a second release profile. Methods include inserting any of these devices into a patient and releasing drug from the device.
Inventor(s):	Heejin Lee, Karen Daniel, Matthew Sansone
Assignee:	Taris Biomedical LLC
Application Number:	US16/936,554
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

Drugs Protected by US Patent 12,447,241

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Biotech	INLEXZO	gemcitabine hydrochloride	SYSTEM;INTRAVESICAL	219683-001	Sep 9, 2025		RX	Yes	Yes			Y

International Family Members for US Patent 12,447,241

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014309012
Australia	2019203394
Australia	2021282405